Baxter International Inc. Files Q3 2024 10-Q Report
Ticker: BAX · Form: 10-Q · Filed: Nov 12, 2024 · CIK: 10456
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
Related Tickers: BAX
TL;DR
BAX Q3 24 10-Q filed. Financials updated.
AI Summary
Baxter International Inc. reported its third-quarter results for the period ending September 30, 2024. The company's financial performance for the quarter and year-to-date is detailed in this 10-Q filing. Specific financial figures and operational updates are provided within the document.
Why It Matters
This filing provides investors and analysts with the latest financial performance data for Baxter International Inc., crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing and does not inherently present new risks.
Key Numbers
- 2024 Q3 — Reporting Period (Indicates the quarter for which financial results are reported.)
- 2024-09-30 — Period End Date (The specific date marking the end of the reporting period.)
- 2024-01-01 — Year-to-Date Start Date (The beginning of the year for year-to-date financial reporting.)
- 2023-12-31 — Previous Year End Date (Reference point for comparative financial analysis.)
- 2024-07-01 — Q3 Start Date (The beginning of the third fiscal quarter.)
Key Players & Entities
- BAXTER INTERNATIONAL INC (company) — Filer
- 20240930 (date) — Reporting period end date
- 20241112 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ending September 30, 2024.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on November 12, 2024.
What is the company's Central Index Key (CIK)?
The company's Central Index Key (CIK) is 0000010456.
What is the Standard Industrial Classification (SIC) code for Baxter International Inc.?
The SIC code for Baxter International Inc. is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
What is the company's fiscal year end date?
Baxter International Inc.'s fiscal year ends on December 31.
Filing Stats: 4,790 words · 19 min read · ~16 pages · Grade level 16.8 · Accepted 2024-11-12 16:38:19
Key Financial Figures
- $1.00 — ange on which registered Common Stock, $1.00 par value BAX (NYSE) New York Stock Exc
Filing Documents
- bax-20240930.htm (10-Q) — 2065KB
- bax-20240930xex102.htm (EX-10.2) — 18KB
- bax-20240930xex103.htm (EX-10.3) — 141KB
- bax-20240930xex311.htm (EX-31.1) — 10KB
- bax-20240930xex312.htm (EX-31.2) — 9KB
- bax-20240930ex321.htm (EX-32.1) — 4KB
- bax-20240930xex322.htm (EX-32.2) — 4KB
- 0001628280-24-047221.txt ( ) — 11925KB
- bax-20240930.xsd (EX-101.SCH) — 69KB
- bax-20240930_cal.xml (EX-101.CAL) — 128KB
- bax-20240930_def.xml (EX-101.DEF) — 389KB
- bax-20240930_lab.xml (EX-101.LAB) — 855KB
- bax-20240930_pre.xml (EX-101.PRE) — 625KB
- bax-20240930_htm.xml (XML) — 2260KB
Financial Statements (unaudited)
Financial Statements (unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Income (Loss) 3 Condensed Consolidated Statements of Comprehensive Income (Loss ) 4 Condensed Consolidated Statements of Changes in Equity 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 33 Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 51 Item 4.
Controls and Procedures
Controls and Procedures 52 PART II. OTHER INFORMATION 53 Item 1.
Legal Proceedings
Legal Proceedings 53
Risk Factors
Item 1A. Risk Factors 53 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 53
Other Information
Item 5. Other Information 53 Item 6. Exhibits 54 Signature 55
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements Baxter International Inc. Condensed Consolidated Balance Sheets (unaudited) (in millions, except share information) September 30, 2024 December 31, 2023 Current assets: Cash and cash equivalents $ 1,420 3,078 Accounts receivable, net of allowances of $ 65 in 2024 and $ 62 in 2023 1,729 1,719 Inventories 2,103 1,918 Prepaid expenses and other current assets 720 706 Current assets of discontinued operations 2,892 2,179 Total current assets 8,864 9,600 Property, plant and equipment, net 2,833 2,871 Goodwill 5,783 5,793 Other intangible assets, net 5,449 5,918 Operating lease right-of-use assets 327 336 Other non-current assets 886 809 Non-current assets of discontinued operations 2,534 2,949 Total assets $ 26,676 $ 28,276 Current liabilities: Current maturities of long-term debt and finance lease obligations $ 2,498 $ 2,667 Accounts payable 841 881 Accrued expenses and other current liabilities 1,772 1,915 Current liabilities of discontinued operations 1,089 1,040 Total current liabilities 6,200 6,503 Long-term debt and finance lease obligations, less current portion 10,437 11,089 Operating lease liabilities 259 265 Other non-current liabilities 1,263 1,400 Non-current liabilities of discontinued operations 575 551 Total liabilities 18,734 19,808 Commitments and contingencies Equity: Common stock, $ 1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2024 and 2023 683 683 Common stock in treasury, at cost, 173,032,822 shares in 2024 and 175,861,893 shares in 2023 ( 11,084 ) ( 11,230 ) Additional contributed capital 6,391 6,389 Retained earnings 15,529 16,114 Accumulated other comprehensive loss ( 3,647 ) ( 3,554 ) Total Baxter stockholders' equity 7,872 8,402 Noncontrolling interests 70 66 Total equity 7,942 8,468 Total liabilities and equity $ 26,676 $ 28,276 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Baxter Int